Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by johnny007on Nov 15, 2019 3:13am
136 Views
Post# 30354677

RE:23k in revenue for the quarter?

RE:23k in revenue for the quarter?No revenue was announced, but financials or MD&A should included a statement about test count and as usual they were not put on the receivables.

All in USD 2Q19 -> 3Q19 sequentially

- So the $2.8M collected at 11.5c (CAD) all gone. (Tripp's biggest play?)

- Cash $0.75M -> $0.41M: $0.34M less

PAYED
+ Current Liabilities down from $6.6M -> $4.26M: $2.3M less!
+ Total Liabilities down from $13.62M -> $8.56M: $5M less!
+ Equity $-9.56M -> $-4.97M: $4.6M more! (still negative though)

Either Tripp found idiots paying for 11.5c in the private placment and this would include Rory B Riggs as an idiot as well - or there is something hidden we don't see yet ;-)

So all we can say is they have halved the liabilities and stabilities the balance sheet,
but sales activity is missing in action still - needs some explanation.

Bullboard Posts